|  | Cancer | Lymphoma

Early Lymphoma Detection: Diagnostic Tests and Their Roles

Lymphoma diagnosis requires a combination of clinical assessment, laboratory tests, imaging, and tissue biopsy. No single test confirms lymphoma; the workup is stepwise.

1. Complete Blood Count (CBC) with Differential

  • May show lymphocytosis, anemia, thrombocytopenia, or leukoerythroblastic picture.
  • Not diagnostic; nonspecific.

2. Comprehensive Metabolic Panel (CMP) & LDH

  • LDH: Elevated in aggressive lymphomas (tumor burden, cell turnover); prognostic marker (IPI score).
  • Liver/kidney function, electrolytes, calcium, uric acid (tumor lysis risk).

3. Inflammatory Markers

  • ESR, CRP – nonspecific elevation; may correlate with B symptoms.

4. Serologic/Virologic Testing

  • HIV, HTLV-1, HBV, HCV, EBV – associated with specific lymphoma subtypes; guide therapy.

5. Imaging

  • CT neck/chest/abdomen/pelvis (with contrast): Standard for staging (Ann Arbor), assessing nodal/extranodal involvement, organomegaly.
  • PET-CT (FDG): Gold standard for staging FDG-avid lymphomas (DLBCL, HL); assesses metabolic activity, guides biopsy site, monitors response (Deauville score).
  • MRI: CNS involvement, spinal cord compression.
  • Ultrasound: Initial nodal assessment, guided biopsy.

6. Tissue Biopsy (Definitive Diagnosis)

  • Excisional lymph node biopsy – preferred; preserves architecture for histology, immunophenotyping (IHC), flow cytometry, FISH, molecular studies.
  • Core needle biopsy – if excision not feasible; must be adequate for subtyping.
  • FNA alone is insufficient for primary diagnosis (loss of architecture).

7. Bone Marrow Biopsy & Aspiration

  • Staging for many NHL subtypes (e.g., follicular, mantle cell, SLL/CLL).
  • Not always needed for early-stage HL or if PET-CT negative.

8. Lumbar Puncture

  • If CNS symptoms, high-risk subtypes (Burkitt, lymphoblastic, DLBCL with testis/breast involvement), or PET-CT suggestive.

9. Molecular & Genetic Profiling

  • FISH for translocations (t(14;18) BCL2, t(11;14) CCND1, t(8;14) MYC).
  • Next-generation sequencing panels for prognosis/targeted therapy.

Workflow Summary

Clinical suspicion → CBC, LDH, CT/PET-CT → Excisional biopsy → IHC/flow/molecular → Subtype classification (WHO) → Staging (Ann Arbor/Lugano) → Risk stratification (IPI, FLIPI, MIPI) → Treatment planning.

Early referral to hematology/oncology optimizes diagnostic accuracy and timely therapy.

Lymphoma - Related Articles